Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB)

Sternberg, Cora N.; Skoneczna, Iwona; Castellano, Daniel; Théodore, Christine; Blais, Normand; Voog, Éric; Bellmunt, Joaquim; Peters, F. P. J.; Le-Guennec, Solenn; Cerbone, Linda; Machiels, Jean‐Pascal

doi:10.1159/000354085

Cited by 32 publications

(15 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cisplatin are employed for the treatment of a variety of tumors, including testicular (Juliachs et al, 2013), ovarian (Mir et al, 2013), head and neck (Pendleton et al, 2013), colorectal (Germani et al, 2013), bladder (Sternberg et al, 2013) and lung cancers (Shin et al, 2013), as a single agent or in combination with other anticancer agents. The prominent mechanism that cisplatin exerts for anticancer effects involves the generation of DNA lesions followed by the activation of the DNA damage response and the induction of mitochondrial apoptosis (Galluzzi et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-100 Resensitizes Resistant Chondrosarcoma Cells to Cisplatin through Direct Targeting of mTOR

Zhu

Wang²,

Zhang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Chondrosarcomas are malignant cartilage-forming tumors of bone which exhibit resistance to both chemotherapy and radiation treatment. miRNAs have been well demonstrated to regulate gene expression and play essential roles in a variety of biological processes, including proliferation, differentiation, migration, cell cycling and apoptosis. In this study, we obtained evidence that miR-100 acts as a tumor suppressor in human chondrosarcomas. Interestingly, cisplatin resistant chondrosarcoma cells exhibit decreased expression of miR-100 compared with parental cells. In addition, we identified mTOR as a direct target of miR-100. Overexpression of miR-100 complementary pairs to the 3' untranslated region (UTR) of mTOR, resulted in sensitization of cisplatin resistant cells to cisplatin. Moreover, recovery of the mTOR pathway by overexpression of S6K desensitized the chondrosarcoma cells to cisplatin, suggesting the miR-100-mediated sensitization to cisplatin dependent on inhibition of mTOR. In summary, the present studies highlight miR-100 as a tumor suppressor in chondrosarcoma contributing to anti-chemoresistance. Overexpression of miR-100 might be exploited as a therapeutic strategy along with cisplatin-based combined chemotherapy for the treatment of clinical chondrosarcoma patients.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA-100 Resensitizes Resistant Chondrosarcoma Cells to Cisplatin through Direct Targeting of mTOR

Zhu

Wang²,

Zhang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Studies were further excluded due to the following reasons: non-GC/MVAC chemotherapy-related RCTs (Wu et al, 2016); blank control studies (Narayanan et al, 2015); non-RCTs (Zhuo et al, 2016); RCTs comparing the same drugs but different dosage or application strategies (Wu et al, 2017); nonchemotherapy-or immunotherapy-related RCTs (Huang et al, 2017); studies without AMUC patients ; studies that did not report certain chemotherapeutic regimens (Resnick et al, 2013); duplicated reports (Jallad et al, 2014); conference abstract (Bianchi et al, 2014); and retraction study (Bianchi et al, 2014). Finally, 19 articles were included in our analysis (Logothetis et al, 1990;Bellmunt et al, 1997;Saxman et al, 1997;McCaffrey et al, 1997;Siefker-Radtke et al, 2002;Dreicer et al, 2004;Bamias et al, 2004;von der Maase et al, 2005;Lorusso et al, 2005;Dogliotti et al, 2007;Bellmunt et al, 2012;De Santis et al, 2012;Sternberg et al, 2013;Bamias et al, 2013;Hussain et al, 2014;Krege et al, 2014;Miller et al, 2016;Cao et al, 2018) (Figure 1, Table 1).…”

Section: Literature Searchmentioning

confidence: 99%

Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis

Huang

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Background: Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) have been the first-line treatments for advanced or metastatic urothelial carcinoma (AMUC). However, their effects are unsatisfactory, and more drugs and regimens still need to be explored. Objective: We aimed to comprehensively compare all possible regimens with GC or MVAC in randomized controlled trials (RCTs) by network meta-analysis. Methods: We searched the PubMed, Embase, and Cochrane databases for RCTs that evaluated regimens compared to GC or MVAC on AMUC patients. The major outcomes were progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). A network meta-analysis was used to assess the effectiveness and safety of the included treatment regimens, and the regimens were then clustered by the average linkage method. Results: A total of 19 trials that assessed 3,363 AMUC patients were included. For PFS, paclitaxel plus GC (PGC) was significantly superior to GC (log hazard ratio (HR): −0.16; 95% confidence interval (CI): −0.32, 0.00) with a moderate level of reliability. However, there was no significant difference between PGC and MVAC (log HR: −0.03; 95% CI: −0.27, 0.20). For OS, PGC was significantly superior to GC (log HR:−0.17; 95% CI: −0.33, −0.00) with a moderate reliability level but not significantly different from MVAC (log HR: −0.10; 95% CI: −0.35, 0.15). Analysis of ORR showed that PGC was superior to MVAC (log odds ratio (OR): 0.59; 95% CI: 0.02, 1.16) with a low reliability level and GC (log OR: 0.41; 95% CI: 0.12, 0.71) with a moderate reliability level. In the cluster results, PGC and sorafenib plus GC (GCS) exhibited relative advantages in efficiency, followed by MVAC and apatorsen plus GC (GCA); however, PGC, gemcitabine plus carboplatin (GP), and MVAC had more serious side effects. Conclusions: In our analysis, PGC was superior to MVAC and GC in only the ORR results and superior to GC in the OS and PFS results but was not significantly different from MVAC. More individualized therapies with targeted drugs need to be studied.

show abstract

“…Larotaxel is under clinical evaluation as a single agent or in combination therapy for urethral bladder cancer, advanced pancreatic cancer, advanced NSCLC and metastatic breast cancer (Figure 3) [54–57]. A Phase III trial of larotaxel with cisplatin for locally advanced/metastatic urothelial tract or bladder cancer suggested that it does not improve outcomes versus cisplatin/gemcitabine [58]. Ortataxel is currently under Phase II evaluation for taxane-refractory NSCLC and metastatic breast cancer [59], as well as recurrent glioblastoma [60].…”

Section: Clinical Development Of Taxane Anticancer Agentsmentioning

confidence: 99%

Taxane anticancer agents: a patent perspective

Ojima

Lichtenthal

Lee

et al. 2015

Expert Opinion on Therapeutic Patents

177

109

View full text Add to dashboard Cite

Introduction Paclitaxel and docetaxel were two epoch-making anticancer drugs and have been successfully used in chemotherapy for a variety of cancer types. In 2010, a new taxane, cabazitaxel, was approved by FDA for use in combination with prednisone for the treatment of metastatic hormone-refractory prostate cancer. Albumin-bound paclitaxel (nab™-paclitaxel; abraxane) nanodroplet formulation was another notable invention (FDA approval 2005 for refractory, metastatic, or relapsed breast cancer). Abraxane in combination with gemcitabine for the treatment of pancreatic cancer was approved by FDA in 2013. Accordingly, there have been a huge number of patent applications dealing with taxane anticancer agents in the last five years. Thus, it is a good time to review the progress in this area and find the next wave for new developments. Area covered This review article covers the patent literature from 2010 to early 2015 on various aspects of taxane-based chemotherapies and drug developments. Expert opinion Three FDA-approved taxane anticancer drugs will continue to expand their therapeutic applications, especially through drug combinations and new formulations. Inspired by the success of abraxane, new nano-formulations are emerging. Highly potent new-generation taxanes will play a key role in the development of efficacious tumor-targeted drug delivery systems.

show abstract

Larotaxel with Cisplatin in the First-Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer: A Randomized, Active-Controlled, Phase III Trial (CILAB)

Cited by 32 publications

References 18 publications

MicroRNA-100 Resensitizes Resistant Chondrosarcoma Cells to Cisplatin through Direct Targeting of mTOR

MicroRNA-100 Resensitizes Resistant Chondrosarcoma Cells to Cisplatin through Direct Targeting of mTOR

Efficacy and Safety of Chemotherapy Regimens in Advanced or Metastatic Bladder and Urothelial Carcinomas: An Updated Network Meta-Analysis

Taxane anticancer agents: a patent perspective

Contact Info

Product

Resources

About